Klotho
CognitiveLongevity protein / researchExperimental
Transmembrane and soluble anti-aging protein that is an FGF23 co-receptor. Shop “Klotho” vials are not an FDA-approved drug and are often fragments or poorly characterized proteins.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- ~130 kDa (full-length protein)
- Half-life
- —
- Unit
- mg
- Administration Route
- Research only
- Frequency
- —
- Last updated
- Aug 23, 2026
- Targets
- FGFR/FGF23Aging-related pathways
Overview
Transmembrane and soluble anti-aging protein that is an FGF23 co-receptor. Shop “Klotho” vials are not an FDA-approved drug and are often fragments or poorly characterized proteins.
Protocol
- Dosage Range
- Not established as a drug
- Frequency
- —
- Cycle
- —
- Administration Route
- Research only
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Science
Mechanism of Action
α-Klotho complexes with FGF receptors for FGF23 signaling (phosphate/vitamin D) and circulating soluble Klotho is studied for cognitive and vascular aging in animals.
Origin
Endogenous protein; research reagents vary widely.
Targets
FGFR/FGF23Aging-related pathways
Studies
Benefits
Aging-biology research
Potential Side Effects
Side Effects
- Unknown for unregulated vials
References
- PMID 11780019External reference